It depends on the standard you follow. As of September 2026, Zoetis Inc. (ZTS) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 28.4% / 30% · (Cash+Inv) / Mkt Cap (36m) 4.81% / 30% · Interest income / Revenue 0.71% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 28.4% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 4.81% / 33% · Receivables / Mkt Cap (36m) 5.31% / 49% · Interest income / Revenue 0.71% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 28.4% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 4.81% / 33.33% · Receivables / Mkt Cap (24m) 5.31% / 33.33% · Interest income / Revenue 0.71% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 59.5% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 12.3% / 33.33% · Receivables / Avg Assets (4Q) 10.5% / 33.33% · Interest income / Revenue 0.71% / 5% | Fail |
| FTSE | Debt / Total Assets 60.0% / 33.33% · (Cash+ST Inv) / Total Assets 10.2% / 33.33% · (Cash+Recv) / Total Assets 21.4% / 33.33% · Interest income / Revenue 0.71% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Zoetis Inc. (ZTS) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Zoetis Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.71% of each dividend: Zoetis Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Zoetis Inc. (NYSE: ZTS) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $33.9B. The Maz Rating grades it against the other companies in its sector.
Zoetis Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $83.37, Zoetis Inc. trades at 14.3x trailing earnings, 3.6x sales and 10.5x book value, with an EV/EBITDA of 11.0. Over the last twelve months it generated about $9.4B of revenue and $2.4B of net income. It runs a gross margin of 71.0%, an operating margin of 36.3% and a net margin of 26.1%. It shows return on equity of 76.4%, return on invested capital of 20.9% and a free cash flow yield of 6.6%. On the balance sheet: a debt-to-equity ratio of 2.80 and a current ratio of 2.35. Over the past 52 weeks the share price ranged from $68.77 to $132.49, with a beta of 0.68.
Zoetis Inc. pays a dividend yielding 2.51%, with 36% of earnings paid out. Its Maz Dividend Score is 2.77 out of 5, ranked against the other dividend payers in its sector (Safety 1.90, Growth 3.77, Yield 4.30, Consistency 2.80).
32 Wall Street analyst ratings cover the stock: 1 Strong Buy, 13 Buy and 18 Hold, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.